Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rain Enhancement Technologies

2.57
-0.0548-2.09%
Post-market: 2.46-0.1052-4.10%16:00 EDT
Volume:7.29K
Turnover:18.38K
Market Cap:19.46M
PE:-1.12
High:2.68
Open:2.51
Low:2.38
Close:2.62
Loading ...

Company Profile

Company Name:
Rain Enhancement Technologies
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
1659 Chinaberry Ct.,Naples,Florida,United States
Zip Code:
34105
Fax:
- -
Introduction:
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

Directors

Name
Position
Charles Wert
Chief Executive Officer, Director
Harry L. You
Chairman, Director
Kenneth Rivers
Director
Roland Rapp
Director
Walter Skowronski
Director

Shareholders

Name
Position
Charles Wert
Chief Executive Officer, Director
Oanh Truong
Chief Financial Officer